EP2851085B1 - Protein ccomposition sterilized by radiation - Google Patents

Protein ccomposition sterilized by radiation Download PDF

Info

Publication number
EP2851085B1
EP2851085B1 EP13791568.2A EP13791568A EP2851085B1 EP 2851085 B1 EP2851085 B1 EP 2851085B1 EP 13791568 A EP13791568 A EP 13791568A EP 2851085 B1 EP2851085 B1 EP 2851085B1
Authority
EP
European Patent Office
Prior art keywords
protein
activity
proteins
sterile composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13791568.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2851085A4 (en
EP2851085A1 (en
Inventor
Yukako Kageyama
Kentaro Fujinaga
Ayuko YAMAGUCHI
Susumu Honda
Makoto Satake
Hiroaki Kaneko
Ayumi ISHIWARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Pharma Ltd
Teijin Ltd
KM Biologics Co Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Teijin Pharma Ltd
Teijin Ltd
KM Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Teijin Pharma Ltd, Teijin Ltd, KM Biologics Co Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to PL13791568T priority Critical patent/PL2851085T3/pl
Publication of EP2851085A1 publication Critical patent/EP2851085A1/en
Publication of EP2851085A4 publication Critical patent/EP2851085A4/en
Application granted granted Critical
Publication of EP2851085B1 publication Critical patent/EP2851085B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Definitions

  • the present invention relates to a sterile composition of a protein which retains its function as it is contained in an aliphatic polyester.
  • Natural and synthetic proteins are becoming more and more important as drugs. When they are used for medical applications, their products must be sterilized. As means of sterilization, there are known heat sterilization in an autoclave, sterilization with ionizing radiation such as a ⁇ ray or electron beam, gas sterilization with an ethylene oxide gas, plasma sterilization with hydrogen peroxide, and separate sterilization using a chemical sterilant comprising a glutaraldehyde formulation or a filter.
  • ionizing radiation such as a ray or electron beam
  • gas sterilization with an ethylene oxide gas gas sterilization with an ethylene oxide gas
  • plasma sterilization with hydrogen peroxide and separate sterilization using a chemical sterilant comprising a glutaraldehyde formulation or a filter.
  • a chemical sterilant comprising a glutaraldehyde formulation or a filter.
  • Sterilization with ethylene oxide has possibilities that a by-product may be produced by a chemical reaction and that a highly toxic residual gas may adversely affect
  • Sterilization with a chemical sterilant has a problem that the resistance to a sterilant of a protein and changes in pH, ion intensity and temperature must be taken into consideration. Then, to manufacture pharmaceuticals and medical products containing or immobilizing a protein, their production processes must be entirely made in sterile conditions and a huge amount of production cost is required.
  • EP0437095 teaches that a neutralized oxidized cellulose product combined with heparin or a heparin fragment (nORC) can be sterilized by gamma-ray irradiation.
  • nORC heparin fragment
  • EP0562864 discloses a composite wound care substance containing a collagen sponge matrix, a second bioabsorbable polymer such as an oxidized regenerated cellulose (ORC) dispersed fiber and an active agent such as peptide.
  • ORC oxidized regenerated cellulose
  • the active agent may be contained in the matrix, the bioabsorbable polymer or both of them and that the composite sponge substance can be sterilized while it is packaged.
  • US5730933 discloses a method of sterilizing biologically active peptide with gamma-ray or electron-beam irradiation without the loss of the biological activity of the peptide.
  • This method is a technology comprising the steps of forming a mixture of biologically active peptide and a foreign protein such as gelatin, freezing or lyophilizing this mixture, and irradiating it.
  • a foreign protein such as gelatin
  • WO2000/033893 discloses a complex of therapeutic peptide and a polysaccharide selected from the group consisting of oxidized regenerated cellulose, neutralized oxidized regenerated cellulose and mixtures thereof. This document teaches that when peptide is formulated together with an effective amount of the polysaccharide before sterilization with ionizing radiation, the biological activity of the peptide therapeutic agent is not lost and is stabilized if peptide is sterilized with ionizing radiation.
  • JP-A 2011-47089 discloses a process for producing an enzyme-containing nanofiber having excellent enzyme activity.
  • a spinning solution containing an enzyme and a polymer dissolved in a nonaqueous solvent is spun by an electrostatic spinning method to form a zymogen nanofiber which is then imparted with water and dried.
  • this document is silent about the sterilization of the enzyme-containing nanofiber.
  • the present invention is defined by the claims. It is an object of the present invention to provide a sterile composition which retains the structure and function of a protein.
  • the inventors of the present invention conducted intensive studies to solve the above problem and found that, surprisingly, when a protein is contained in an aliphatic polyester, the structural change and functional deterioration of the protein caused by sterilization with radiation and either one or both of the above change and the above deterioration caused by storage after sterilization with radiation can be suppressed.
  • the present invention was accomplished based on this finding.
  • the present invention is a sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation.
  • the present invention is a sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation.
  • the protein used in the present invention is not particularly limited.
  • Preferred examples of the protein include hemostat proteins typified by fibrinogen and thrombin, enzymes typified by asparaginase, catalase, superoxide dismutase and lipase, transport proteins typified by hemoglobin, serum albumin and low density lipoprotein, muscle proteins typified by actin and myosin, defense proteins typified by antibodies and complements, toxin proteins typified by diphtheria toxin, botulinum toxin and snake venom, protein hormones typified by insulin, growth factors and cytokine, storage proteins typified by ovalbumin and ferritin, structural proteins typified by collagen and keratin, and growth factors typified by epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), granulocyte-
  • the protein used in the present invention may be of animal origin or manufactured by a genetic recombination technique. If it is of animal origin, it is preferably of human origin.
  • the protein manufactured by the genetic recombination technique may be a variant obtained by replacing the amino acid sequence to another amino acid sequence if the essential bioactivity is the same. Proteins obtained by modifying these proteins and mixtures thereof may also be used.
  • additives which are pharmaceutically acceptable may be added.
  • Preferred examples of the additives include blood coagulation factor XIII, albumin, isoleucine, glycine, arginine, glutamic acid, phenylalanine, histidine, surfactants, sodium chloride, sugar alcohols (such as glycerol, mannitol, etc.), trehalose, sodium citrate, aprotinin and calcium chloride. At least one selected from the group of these is used.
  • the protein used in the present invention or a mixture of the protein and additives may be dispersed in an aliphatic polyester as molecules but preferably as particles formed by the aggregation of the molecules (may be referred to as "protein particles” including mixed particles with the additives).
  • the aliphatic polyester used in the present invention is preferably a bioabsorbable or biodegradable polymer.
  • the bioabsorbable polymer include polylactic acid, polyglycolic acid, polylactic acid-polyglycolic acid copolymer, polycaprolactone, polylactic acid-polycaprolactone copolymer, polyglycerol sebacic acid, polyhydroxy alkanoic acid, polybutylene succinate and derivatives thereof.
  • polyglycolic acid, polylactic acid, polycaprolactone, copolymers thereof and mixtures thereof are preferred, and polylactic acid and polylactic acid-glycolic acid copolymer are most preferred.
  • a stereocomplex of poly-L-lactic acid and poly-D-lactic acid may be used.
  • the molecular weight of the aliphatic polyester used in the present invention is 1 x 10 3 to 5 x 10 6 , preferably 1 x 10 4 to 1 x 10 6 , much more preferably 5 x 10 4 to 5 x 10 5 .
  • the terminal structure of the polymer and a catalyst for polymerizing the polymer may be arbitrarily selected.
  • another polymer or another compound may be used in combination as long as the object of the present invention is not impaired.
  • examples of these include copolymers, polymer blends and compound mixtures.
  • the aliphatic polyester used in the present invention preferably has high purity. Especially, the contents of additives and plasticizer contained in the aliphatic polyester and residues such as residual catalyst, residual monomers and residual solvent used for molding and post-processing are preferably as low as possible. Especially when the composition is used for medical purposes, it is necessary to reduce these contents to values below safety standards.
  • the expression "containing the protein” means that at least part of the protein enters the inside of the aliphatic polyester. This state is distinguished from the state of a lyophilized complex in which the protein is existent on the surface of the composition or in the voids of the composition.
  • the form of the sterile composition of the present invention is in the form of a fiber, film, sheet, plate-like body, tube-like body, linear body, rod-like body, cushion material, foam or porous body.
  • the molding method for producing a molded product is not particularly limited if it is a method in which the structural change and the reduction of the activity of the protein are suppressed.
  • suitable molding techniques such as extrusion molding, injection molding, calender molding, compression molding, blow molding, vacuum forming, powder molding, cast molding and casting may be employed.
  • the sterile composition of the present invention is suitable for the production of fibers and films, and any one of molding techniques which have been employed for the production of plastic fibers or films may be employed.
  • extrusion molding techniques such as inflation extrusion molding and T die extrusion molding, and calendering and casting techniques may be used.
  • the above molding may be melt molding or solution molding, out of which solution molding is preferred in order to facilitate the dispersion of the protein so as to prevent the functional deterioration of the protein.
  • the fiber form as used herein refers to a 3-D molded body formed by the lamination, weaving, knitting or another technique of one or a plurality of fibers.
  • the fiber form is, for example, a nonwoven fabric. Further, a tube and a mesh obtained by processing the nonwoven fabric are included in the fiber form.
  • the average fiber diameter of the sterile composition having a fiber form of the present invention is, for example, 0.01 to 50 ⁇ m and may be suitably determined by a person skilled in the art according to the intended use.
  • the sterile composition having a fiber form of the present invention may be in the form of a long fiber.
  • the long fiber is a fiber formed without adding the step of cutting a fiber in the course of transition from spinning to the processing of a fiber molded body. It can be formed by electrospinning, span bonding and melt blowing methods. Out of these, the electrospinning method is preferred.
  • the electrospinning method is a method in which a fiber molded body is obtained on an electrode by applying a high voltage to a solution containing a polymer.
  • the process comprises the steps of preparing a spinning solution containing a polymer, applying a high voltage to the solution, jetting the solution, forming a fiber molded body by evaporating the solvent from the jetted solution, eliminating the charge of the formed fiber molded body as an optional step, and accumulating the fiber molded body by the charge loss.
  • the step of preparing a spinning solution in the electrospinning method will be explained.
  • the spinning solution in the present invention is not particularly limited, an emulsion containing an organic solvent solution of an aliphatic polyester and an aqueous solution of a protein, a suspension containing an organic solvent solution of an aliphatic polyester and protein particles, or an organic solvent solution containing an aliphatic polyester and a protein may be used as the spinning solution.
  • a suspension containing an organic solvent solution of an aliphatic polyester and protein particles is preferred.
  • the concentration of the aliphatic polyester in the aliphatic polyester solution is preferably 1 to 30 wt%.
  • concentration of the aliphatic polyester is lower than 1 wt%, it is difficult to form a fiber molded body disadvantageously.
  • concentration is higher than 30 wt%, the fiber diameter of the obtained fiber molded body becomes large disadvantageously.
  • concentration of the aliphatic polyester contained in the organic solvent solution is more preferably 2 to 20 wt%.
  • the solvent for the aliphatic polyester is not particularly limited if it can dissolve the aliphatic polyester, evaporates in the spinning step and can form a fiber. Only one solvent or a combination of two or more solvents may be used. Examples of the solvent include chloroform, 2-propanol, toluene, benzene, benzyl alcohol, dichloromethane, carbon tetrachloride, cyclohexane, cyclohexanone, trichloroethane, methyl ethyl ketone, ethyl acetate and mixtures thereof.
  • a solvent such as acetone, ethanol, methanol, tetrahydrofuran, 1,4-dioxane, 1-propanol, phenol, pyridine, acetic acid, formic acid, hexafluoro-2-propanol, hexafluoroacetone, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, N-methyl-2-pyrrolidinone, N-methylmorpholine-N-oxide or 1,3-dioxolane may be contained.
  • dichloromethane or ethanol is preferably used from the viewpoints of handling ease and physical properties.
  • the protein in the present invention may be added to and mixed with an organic solvent solution of an aliphatic polyester in a solid, liquid or solution form.
  • the aqueous solvent for the protein is not particularly limited if it can dissolve the protein, forms an emulsion with the organic solvent solution of an aliphatic polyester, evaporates in the spinning step and can form a fiber.
  • physiological saline and buffer solutions may be used.
  • a stabilizer for the protein and additives may be added.
  • a phosphoric acid buffer solution or physiological saline is preferably used.
  • the concentration of the protein in the aqueous solution of the protein used in the present invention is not particularly limited and may be suitably determined according to the characteristic properties of the protein. It is, for example, 0.5 to 50 wt%.
  • the mixing ratio of these solutions is not particularly limited if they form a stable emulsion.
  • the (aqueous solution of protein)/(organic solvent solution of aliphatic polyester) (volume ratio) is 1/100 to 1/2. When this value is larger than 1/2, the emulsion becomes unstable disadvantageously.
  • the method of preparing an emulsion by mixing together an organic solvent solution of an aliphatic polyester and an aqueous solution of a protein is not particularly limited, ultraviolet waves or stirring means may be used.
  • the stirring means high-speed stirring means such as a homogenizer or stirring means such as an attriter or ball mill may be used. Out of these, dispersion with ultrasonic waves is preferred.
  • the spinning solution may be prepared by adding an aliphatic polyester after an emulsion is formed from an organic solvent and an aqueous solution of a protein.
  • the sizes of protein particles are not particularly limited but preferably 0.01 to 100 ⁇ m. It is technically difficult to manufacture protein particles having a particle size smaller than 0.01 ⁇ m, and when the particle size is larger than 100 ⁇ m, dispersibility degrades and the sterile composition becomes brittle disadvantageously.
  • the method of preparing a suspension by mixing together an organic solvent solution of an aliphatic polyester and protein particles is not particularly limited, ultraviolet waves or stirring means may be used.
  • stirring means high-speed stirring means such as a homogenizer or stirring means such as an attriter or ball mill may be used. Out of these, dispersion with ultrasonic waves is preferred.
  • the spinning solution may be prepared by adding an aliphatic polyester after a suspension is formed from an organic solvent and protein particles.
  • protein particles Before the preparation of the suspension, protein particles may be microfabricated.
  • microfabrication there are dry milling and wet milling both of which may be employed and also may be combined in the present invention.
  • Dry milling may be carried out by milling with a ball mill, planetary mill or oscillating mill, by pounding in a mortar with a pestle, or by grinding with a medium stirring type pulverizer, jet mill or stone mill.
  • wet milling is carried out by stirring with a stirrer or kneader having high shear force while protein particles are dispersed in a suitable dispersion medium, or by using a ball mill or bead mill while protein particles are dispersed in a medium. Further, protein particles produced by a spay drier may also be used.
  • the sterilization method used in the present invention is radiation sterilization.
  • the radiation in use include alpha rays, beta rays, gamma rays, neutron rays, electron beams and X-rays. Out of these, gamma rays and electron beams are preferred, and electron beams are most preferred.
  • the sterilization method is not particularly limited, the dose of the radiation is 10 to 80 kGy, preferably 20 to 30 kGy.
  • the temperature condition is not particularly limited, it is -80 to 40°C, preferably -80 to 30°C.
  • the radiation such as alpha rays, positron, gamma rays, neutron rays, electron beams or X-rays strips an electron off from molecules or atoms constituting a substance when it is applied to the substance. A molecular bond is broken upon this, and a highly reactive radical is produced and chemically reacts with a surrounding substance secondarily.
  • the aliphatic polyester containing the protein before radiation sterilization in the present invention may further contain an electron/ion scavenger, energy transfer agent, radical scavenger, antioxidant and plasticizer.
  • electron/ion scavenger include N,N'-tetramethyl phenylenediamine, diphenylenediamine, pyrene and quinone.
  • energy transfer agent include acenaphthene.
  • radical scavenger examples include mercaptans, octahydrophenanthrene, monoalkyl diphenyl ethers, tocopherol, citric acid, butylated hydroxyanisole, butylated hydroxytoluene, t-butyl hydroquinone, propyl gallate and ascorbic acid derivatives.
  • antioxidant examples include BHT, phosphite triesters, phenolic antiaging agents and organic thio acid salts. Additives that are generally accepted as safe for use in foods and pharmaceuticals are preferred.
  • the amount of the additive which is not particularly limited is, for example, 0.01 to 10 wt% based on the aliphatic polyester in the sterile composition.
  • the aliphatic polyester containing the protein in the sterilization step preferably contains no water.
  • the water content of the aliphatic polyester is preferably not more than 10 wt%, more preferably not more than 4 wt%, much more preferably substantially 0 wt%.
  • the aliphatic polyester containing the protein may be wrapped in a packaging material to be sterilized with radiation.
  • a packaging material a material having high gas barrier properties such as aluminum is preferably used.
  • the aliphatic polyester may be hermetically sealed and packaged together with a deoxidant or desiccant or while an inert gas is filled into the package after degasification, or both methods may be combined together.
  • the deoxidant and the desiccant ones which do no harm to the human body and are not deactivated upon exposure to radiation are preferred.
  • the sterile composition of the present invention may be used as a medical material which requires the function and sterility of a protein.
  • reaction solution 100 ⁇ L of the S-2238 test team chromogenic substrate (1 mM: Daiichi Pure Chemicals Co., Ltd.) was added to and mixed with the obtained reaction solution under agitation to carry out a reaction at 37°C for 5 minutes, and 800 ⁇ L of a 0.1 M citric acid solution was added to terminate the reaction. 200 ⁇ L of the reaction solution was transferred to 96 well plates to measure OD405/650.
  • Recombinant thrombin (JPU Thrombin Standard 400 U/mL or WHO/US Thrombin Standard 110 IU/mL) diluted with the above buffer to 4, 2, 1, 0.5 and 0.25 U/mL in the case of JPU and to 6, 3, 1.5, 0.75 and 0.375 IU/mL in the case of IU was used as a standard.
  • 100 ⁇ L of the S-2238 test team chromogenic substrate (1 mM: Daiichi Pure Chemicals Co., Ltd.) was added to and mixed with the obtained reaction solution under agitation to carry out a reaction at 37°C for 7 minutes, and then 800 ⁇ L of a 0.1 M citric acid solution was added to terminate the reaction. 200 ⁇ L of the reaction solution was transferred to 96 well plates to measure OD405/650.
  • fibrinogen was extracted with a dilution solution to measure the amount of its aggregate by high-speed liquid chromatography.
  • the thicknesses of 15 molded bodies were measured with a measurement force of 0.01 N by means of a high-resolution digimatic measuring unit ((LITEMATIC VL-50 of Mitutoyo Corporation) to calculate the average value as the thickness of the molded body. This measurement was carried out with minimum measurement force that could be used by the measuring unit.
  • the molded body was cut to a size of 50 mm x 100 m to measure its weight so as to calculate the weight of the molded body.
  • the bulk density of the molded body was calculated from the above measurement thickness and weight value.
  • the molded body was cut to a size of 2 cm x 2 cm and immersed in 1 mL of physiological saline for 3 minutes or 3 hours to elute an immobilized enzyme. This process was carried out on three molded bodies to measure their weight changes so as to obtain the average value of extraction rate calculated from the following equation.
  • a continuous fluorometric lipase test kit (manufactured by PROGEN BIOTECHNIK GMBH) was used to measure the activity of lipase.
  • the recovery rate of activity was calculated from the following equation.
  • the amount of the active enzyme was calculated in terms of concentration from the value of activity.
  • the theoretical weight of the immobilized enzyme per unit area was calculated from wt% of the charged enzyme powder and the weight of the composition.
  • Recovery rate of activity % amount of active enzyme mg / cm 2 / theoretical weight of immobilized enzyme per unit area mg / cm 2 ⁇ extraction rate ) ⁇ 100
  • Retention rate of activity % recovery rate of activity after sterilization % / recovery rate of activity before sterilization % ) ⁇ 100
  • thrombin-containing particles prepared by lyophilizing an aqueous solution containing 1 mg/mL of recombinant thrombin, sodium chloride, sodium citrate, calcium chloride and mannitol and having a pH of 7
  • dichloromethane was added to the resulting dispersion
  • a polyglycolic acid-polylactic acid copolymer Purasorb PDLG5010 of PURAC
  • a spinning solution having a thrombin-containing particle/polyglycolic acid-polylactic acid copolymer ratio of 100 (1.69 as thrombin)/100 (w/w).
  • Spinning was carried out by an electrospinning method to obtain a sheet-like fiber molded body.
  • the obtained fiber molded body had a thickness of 131 ⁇ m, a weight of 1.44 mg/cm 2 and a bulk density of 111 mg/cm 3 .
  • the obtained sheet was cut to a diameter of 1 cm, and the protein was extracted with 200 ⁇ L of physiological saline to measure its activity. As a result, the measurement value of activity was 26.7 U/cm 2 .
  • the obtained sheet was sterilized by exposure to a 20 kGy electron beam and kept at 40°C and 75 %RH for 1 month to measure the activity of thrombin.
  • the retention rate of the activity of thrombin right after exposure to the electron beam was 79 %.
  • the retention rate of activity after 1 month was 78 %, and no reduction in the activity of thrombin was observed during storage.
  • thrombin-containing particles prepared by lyophilizing an aqueous solution containing 1 mg/mL of recombinant thrombin, sodium chloride, sodium citrate, calcium chloride and mannitol and having a pH of 7
  • Quinizarin Green SS of Tokyo Chemical Industry Co., Ltd.
  • dichloromethane was added to the resulting dispersion, and a polyglycolic acid-polylactic acid copolymer (Purasorb PDLG5010 of PURAC) was dissolved in the dispersion to a concentration of 10 wt% to prepare a spinning solution having a thrombin-containing particle/polyglycolic acid-polylactic acid copolymer ratio of 100 (1.69 as thrombin)/100 (w/w).
  • Spinning was carried out by the electrospinning method to obtain a sheet-like fiber molded body.
  • the obtained sheet containing the fiber molded body (average thickness: 129 ⁇ m, weight: 1.49 mg/cm 2 , bulk density: 124 mg/cm 3 ) was cut to a diameter of 1 cm, and the protein was extracted with 200 ⁇ L of physiological saline to measure the activity of thrombin. As a result, the measurement value of activity was 40.2 IU/cm 2 .
  • the obtained sheet was sterilized by exposure to a 30 kGy electron beam and kept at 40°C and 75 %RH for 1 month to measure the activity of thrombin.
  • the retention rate of the activity of thrombin right after exposure to an electron beam was 70 %.
  • the retention rate of activity after 1 month was 74 %, and no reduction in the activity of thrombin was observed during storage.
  • thrombin-containing particles prepared by lyophilizing an aqueous solution containing 1 mg/mL of recombinant thrombin, sodium chloride, sodium citrate, calcium chloride and mannitol and having a pH of 7
  • dichloromethane was added to the resulting dispersion
  • a polyglycolic acid-polylactic acid copolymer Purasorb PDLG5010 of PURAC
  • a dope solution having a thrombin-containing particle/polyglycolic acid-polylactic acid copolymer ratio of 100 (1.69 as thrombin)/100 (w/w).
  • the obtained dope solution was used to form a film by a casting method.
  • the coating interval was 127 ⁇ m, and the coating speed was 30.1 mm/sec.
  • the obtained sheet had a thickness of 58 ⁇ m, a weight of 2.9 mg/cm 2 and a bulk density of 504 mg/cm 3 .
  • the obtained sheet was cut to a diameter of 1 cm, and the protein was extracted with 200 ⁇ L of physiological saline to measure the activity of thrombin. As a result, the measurement value of activity was 71.1 IU/cm 2 .
  • the obtained sheet was sterilized by exposure to a 30 kGy electron beam and kept at 40°C and 75 %RH for 1 month to measure the activity of thrombin.
  • the retention rate of the activity of thrombin right after exposure to an electron beam was 75.7 %.
  • the retention rate of activity after 1 month was 82 %, and no reduction in the activity of thrombin was observed during storage.
  • fibrinogen-containing particles prepared by lyophilizing an aqueous solution containing 10 mg/mL of recombinant fibrinogen, arginine, sodium chloride and mannitol and having a pH of 8.5
  • dichloromethane was added to the resulting dispersion, and a polyglycolic acid-polylactic acid copolymer (Purasorb PDLG5010 of PURAC) was dissolved in the dispersion to a concentration of 10 wt% to prepare a spinning solution having a fibrinogen-containing particle/polyglycolic acid-polylactic acid copolymer ratio of 100 (50.85 as fibrinogen)/100 (w/w).
  • the obtained fiber molded body had a thickness of 131 ⁇ m, a weight of 1.44 mg/cm 2 and a bulk density of 110 mg/cm 3 .
  • the obtained sheet was cut to a diameter of 1 cm, and fibrinogen was extracted with a dilution solution to measure the amount of its aggregate by high-speed chromatography. As a result, the amount of the aggregate was 9.79 %.
  • the obtained sheet was sterilized by exposure to a 30 kGy electron beam and kept at 40°C and 75 %RH for 1 month to measure the amount of the aggregate.
  • the amount of the aggregate right after exposure to an electron beam was 18.81 %.
  • the weight of the aggregate after 1 month was 24.14 %.
  • thrombin-containing particles prepared by lyophilizing an aqueous solution containing 1 mg/mL of recombinant thrombin, sodium chloride, sodium citrate, calcium chloride and mannitol and having a pH of 7) to sterilize them, the thrombin-containing particles were kept at 40°C and 75 %RH for 1 month to measure the activity of thrombin.
  • the activity of thrombin before exposure was 404.73 U/vial.
  • the retention rate of the activity of thrombin right after exposure to an electron beam was 51.8 %.
  • the retention rate of activity after 1 month was 17.9 %, and a reduction in the activity of thrombin was observed during storage.
  • thrombin-containing particles prepared by lyophilizing an aqueous solution containing 1 mg/mL of recombinant thrombin, sodium chloride, sodium citrate, calcium chloride and mannitol and having a pH of 7
  • 2-propanol hydroxypropyl cellulose (2.0-2.9 mPa ⁇ s, manufactured by Nippon Soda Co., Ltd.) was dissolved in the resulting dispersion to a concentration of 13 wt% to prepare a dope solution having a thrombin-containing particle/hydroxypropyl cellulose ratio of 100/100 (w/w).
  • Spinning was carried out by the electrospinning method to obtain a sheet-like fiber molded body.
  • the obtained fiber molded body had a thickness of 204 ⁇ m, a weight of 2.08 mg/cm 2 and a bulk density of 101 mg/cm 3 .
  • the obtained sheet was cut to a diameter of 1 cm, and the protein was extracted with 200 ⁇ L of physiological saline to measure its activity. As a result, the measurement value of activity was 110.3 IU/cm 2 .
  • the obtained sheet was sterilized by exposure to a 30 kGy electron beam and kept at 40°C and 75 %RH for 1 month to measure the activity of thrombin. When the activity of thrombin before sterilization was 100 %, the retention rate of the activity of thrombin right after exposure to an electron beam was 68.4 %. The retention rate of activity after 1 month was 54.9 % and a reduction in the activity of thrombin was observed during storage.
  • fibrinogen-containing particles prepared by lyophilizing an aqueous solution containing 10 mg/mL of recombinant fibrinogen, arginine, sodium chloride and mannitol and having a pH of 8.5
  • the thrombin-containing particles were kept at 40°C and 75 %RH for 1 month to measure the amount of an fibrinogen aggregate.
  • the amount of the aggregate before exposure was 6.97 %.
  • the amount of the aggregate right after exposure to an electron beam was 18.51 %.
  • the amount of the aggregate after 1 month was 54.72 %.
  • Example 4 The results (the amount of the fibrinogen aggregate after sterilization and after storage after sterilization) of Example 4 and Comparative Example 3 are shown in Fig. 2 .
  • tissue adhesive Vial 3
  • thrombin-containing particles Bolheal, (registered trademark, the same shall apply hereinafter)
  • tissue adhesive Vial 3
  • thrombin-containing particles Bolheal, (registered trademark, the same shall apply hereinafter
  • tissue adhesive Vial 3
  • polylactic acid PL18 of Purac Biomaterials
  • Spinning was carried out by the electrospinning method to obtain a sheet-like fiber molded body. The obtained sheet was sterilized with a 20 kGy electron beam.
  • the obtained sheet was cut to a size of 2 cm x 2 cm, and the protein was extracted with 1 mL of physiological saline to measure its activity and ELISA.
  • the activity measurement value was 5.0 U/cm 2
  • the ELISA measurement value was 3.4 ⁇ g/cm 2 .
  • the activity measurement value was 7.5 U/cm 2 and the ELISA measurement value was 4.35 ⁇ g/cm 2 . That is, the retention rate of the activity of the sterilized sheet was 73 % of that of the unsterilized sheet.
  • thrombin-containing particles Bolheal tissue adhesive: Vial 3
  • dichloromethane was added to the resulting dispersion, and polylactic acid (PL18 of Purac Biomaterials) was dissolved in the dispersion to a concentration of 10 wt% to prepare a spinning solution having a thrombin-containing particle/polylactic acid ratio of 70 (0.78 as thrombin)/100 (w/w).
  • Spinning was carried out by the electrospinning method to obtain a sheet-like fiber molded body. The obtained sheet was sterilized with a 20 kGy electron beam.
  • the obtained sheet was cut to a size of 2 cm x 2 cm, and the protein was extracted with 1 mL of physiological saline to measure its activity and ELISA.
  • the activity measurement value was 9.575 U/cm 2
  • the ELISA measurement value was 7.0 ⁇ g/cm 2 .
  • the activity measurement value was 11.15 U/cm 2 and the ELISA measurement value was 7.2 ⁇ g/cm 2 . That is, the retention rate of the activity of the sterilized sheet was 86 % of that of the unsterilized sheet.
  • thrombin lyophilized powders Bolheal tissue adhesive: Vial 3
  • dichloromethane was added to the resulting dispersion
  • polylactic acid PL18 of Purac Biomaterials
  • Spinning was carried out by the electrospinning method at a temperature of 22°C and a humidity of not more than 26 % to obtain a sheet-like fiber molded body.
  • the inner diameter of a jet nozzle was 0.8 mm, the voltage was 15 kV, the flow rate of the spinning solution was 3.0 mL/h, and the distance from the jet nozzle to a flat plate was 25 cm.
  • the obtained sheet was sterilized with a 20 kGy electron beam.
  • the obtained sheet was cut to a size of 2 cm x 2 cm, and the protein was extracted with 1 mL of physiological saline to measure its activity and ELISA. As a result, the activity measurement value was 15 U/cm 2 , and the ELISA measurement value was 11 ⁇ g/cm 2 .
  • the activity measurement value was 23 U/cm 2 and the ELISA measurement value was 16 ⁇ g/cm 2 . That is, the retention rate of the activity of the sterilized sheet was 64 % of that of the unsterilized sheet.
  • Thrombin-containing particles (Bolheal) were sterilized with a 20 kGy electron beam.
  • the protein was extracted with 1 mL of physiological saline to measure its activity and ELISA.
  • the activity measurement value was 22.5 U/cm 2 and the ELISA measurement value was 11.5 ⁇ g/cm 2 .
  • the activity measurement value was 68.5 U/cm 2 and the ELISA measurement value was 41.5 ⁇ g/cm 2 . That is, the retention rate of the activity of the sterilized sheet was 32 % of that of the unsterilized sheet.
  • lipase powders derived from pig pancreas, manufactured by Wako Pure Chemical Industries, Ltd., the same shall apply hereinafter
  • dichloromethane was added to the resulting dispersion, and a polylactic acid-glycolic acid copolymer (PDLG5010 of Purac Biomaterials) was dissolved in the dispersion to a concentration of 10 wt% to prepare a spinning solution having a lipase powder/polylactic acid-glycolic acid copolymer ratio of 50/100 (w/w).
  • Spinning was carried out by the electrospinning method at a temperature of 27°C and a humidity of not more than 25 % to obtain a sheet-like fiber molded body.
  • the inner diameter of a jet nozzle was 0.9 mm, the voltage was 15 kV, the flow rate of the spinning solution was 4.0 mL/h, and the distance from the jet nozzle to a flat plate was 25 cm.
  • the lipase extraction rate of the obtained sheet was 79 %.
  • the obtained sheet was sterilized with a 20 kGy electron beam.
  • the obtained sterilized sheet was cut to a size of 1 cm x 1 cm, and lipase was extracted with 1 mL of a lipase buffer contained in a kit to measure its activity. As a result, the recovery rate of activity was 100 %.
  • Dichloromethane was added to lipase powders, and a polylactic acid-glycolic acid copolymer (PDLG5010 of Purac Biomaterials) was dissolved in the resulting mixture to a concentration of 10 wt% to prepare a spinning solution having a lipase powder/polylactic acid ratio of 50/100 (w/w).
  • Spinning was carried out by the electrospinning method at a temperature of 26°C and a humidity of not more than 25 % to obtain a sheet-like fiber molded body.
  • the inner diameter of a jet nozzle was 0.8 mm, the voltage was 15 kV, the flow rate of the spinning solution was 4.0 mL/h, and the distance from the jet nozzle to a flat plate was 25 cm.
  • the lipase extraction rate of the obtained sheet was 63 %.
  • the obtained sheet was sterilized with a 20 kGy electron beam.
  • the obtained sterilized sheet was cut to a size of 1 cm x 1 cm, and lipase was extracted with 1 mL of a lipase buffer contained in a kit to measure its activity. As a result, the recovery rate of activity was 92 %.
  • ⁇ -glucosidase powders (derived from almond, manufactured by Oriental Yeast Co., Ltd, the same shall apply hereinafter) were dispersed in ethanol, dichloromethane was added to the resulting dispersion, and a polylactic acid-glycolic acid copolymer (PDLG5010 of Purac Biomaterials) was dissolved in the dispersion to a concentration of 10 wt% to prepare a spinning solution having a ⁇ -glucosidase powder/polylactic acid-glycolic acid copolymer ratio of 38/62 (w/w). Spinning was carried out by the electrospinning method at a temperature of 27°C and a humidity of not more than 25 % to obtain a sheet-like fiber molded body.
  • PDLG5010 polylactic acid-glycolic acid copolymer
  • the inner diameter of a jet nozzle was 0.9 mm, the voltage was 15 kV, the flow rate of the spinning solution was 4.0 mL/h, and the distance from the jet nozzle to a flat plate was 25 cm.
  • the obtained sheet was cut to a size of 2 cm x 2 cm, it was sterilized with a 20 kGy electron beam.
  • ⁇ -glucosidase was extracted with 1 mL of physiological saline to measure its activity with Tokyogreen- ⁇ Glu. As a result, the recovery rate of activity was 92 %. When activity measurement was made on an unsterilized sheet likewise, the recovery rate of activity was 94 %. It was understood from above that the retention rate of the activity of the sterilized fiber molded body was 98 % of that of the unsterilized fiber molded body and that ⁇ -glucosidase was not deactivated by electron beam sterilization.
  • ⁇ -glucosidase powders were dispersed in ethanol, dichloromethane was added to the resulting dispersion, and a polylactic acid-caprolactone copolymer (PLCA8812 of Taki Chemical Co., Ltd.) was dissolved in the dispersion to a concentration of 10 wt% to prepare a spinning solution having a ⁇ -glucosidase powder/polylactic acid-caprolactone copolymer ratio of 38/62 (w/w).
  • Spinning was carried out by the electrospinning method at a temperature of 27°C and a humidity of not more than 25 % to obtain a sheet-like fiber molded body.
  • the inner diameter of a jet nozzle was 0.9 mm, the voltage was 15 kV, the flow rate of the spinning solution was 3.0 mL/h, and the distance from the jet nozzle to a flat plate was 25 cm.
  • the obtained sheet was cut to a size of 2 cm x 2 cm, it was sterilized with a 20 kGy electron beam.
  • ⁇ -glucosidase was extracted with 1 mL of physiological saline to measure its activity with Tokyogreen- ⁇ Glu. As a result, the recovery rate of activity was 81 %. When activity measurement was made on an unsterilized sheet likewise, the recovery rate of activity was 80 %. It was understood from above that the retention rate of the activity of the sterilized fiber molded body was 101 % of that of the unsterilized fiber molded body and that ⁇ -glucosidase was not deactivated by electron beam sterilization.
  • ⁇ -glucosidase powders were dispersed in ethanol, dichloromethane was added to the resulting dispersion, and polylactic acid (PL18 of Purac Biomaterials) was dissolved in the dispersion to a concentration of 11 wt% to prepare a spinning solution having a ⁇ -glucosidase powder/polylactic acid ratio of 38/62 (w/w).
  • Spinning was carried out by the electrospinning method at a temperature of 27°C and a humidity of not more than 25 % to obtain a sheet-like fiber molded body.
  • the inner diameter of a jet nozzle was 0.9 mm, the voltage was 15 kV, the flow rate of the spinning solution was 3.0 mL/h, and the distance from the jet nozzle to a flat plate was 25 cm.
  • the obtained sheet was cut to a size of 2 cm x 2 cm, it was sterilized with a 20 kGy electron beam.
  • ⁇ -glucosidase was extracted with 1 mL of physiological saline to measure its activity with Tokyogreen- ⁇ Glu. As a result, the recovery rate of activity was 62 %. When activity measurement was made on an unsterilized sheet likewise, the recovery rate of activity was 71 %. It was understood from above that the retention rate of the activity of the sterilized fiber molded body was 87 % of that of the unsterilized fiber molded body and that ⁇ -glucosidase was not deactivated by electron beam sterilization.
  • Lipase powders were sterilized with a 20 kGy electron beam. 1 mL of a lipase buffer was added to 1 mg of the powders to measure the activity of lipase. As a result, the recovery rate of activity was 74 %.
  • ⁇ -glucosidase powders were sterilized with a 20 kGy electron beam. 2 mg of the powders was dissolved in 1 mL of physiological saline to measure the activity of ⁇ -glucosidase with Tokyogreen- ⁇ Glu. As a result, the retention rate of activity was 81 %.
  • the sterile composition of the present invention retains the structure and function of a protein though it is sterilized.
  • the sterile composition of the present invention is used in the manufacturing industry of medical products which require the function and sterility of a protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Moulding By Coating Moulds (AREA)
EP13791568.2A 2012-05-14 2013-05-13 Protein ccomposition sterilized by radiation Active EP2851085B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL13791568T PL2851085T3 (pl) 2012-05-14 2013-05-13 Kompozycja białka sterylizowana promieniowaniem

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012110390 2012-05-14
JP2012110765 2012-05-14
JP2013040593 2013-03-01
PCT/JP2013/063868 WO2013172468A1 (ja) 2012-05-14 2013-05-13 滅菌組成物

Publications (3)

Publication Number Publication Date
EP2851085A1 EP2851085A1 (en) 2015-03-25
EP2851085A4 EP2851085A4 (en) 2015-04-15
EP2851085B1 true EP2851085B1 (en) 2019-06-26

Family

ID=49583866

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13791568.2A Active EP2851085B1 (en) 2012-05-14 2013-05-13 Protein ccomposition sterilized by radiation

Country Status (18)

Country Link
US (1) US10071061B2 (ja)
EP (1) EP2851085B1 (ja)
JP (1) JP5746430B2 (ja)
KR (1) KR102037555B1 (ja)
CN (1) CN104284673B (ja)
AU (1) AU2013261308B2 (ja)
BR (1) BR112014028443B1 (ja)
CA (1) CA2873602C (ja)
DK (1) DK2851085T3 (ja)
ES (1) ES2746300T3 (ja)
HK (1) HK1204947A1 (ja)
IN (1) IN2014DN09621A (ja)
MX (1) MX356545B (ja)
PL (1) PL2851085T3 (ja)
PT (1) PT2851085T (ja)
RU (1) RU2695522C2 (ja)
TW (1) TWI636799B (ja)
WO (1) WO2013172468A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI584825B (zh) * 2012-05-14 2017-06-01 帝人股份有限公司 薄片成形體及止血材
EP3245871A1 (en) 2014-04-30 2017-11-22 Matoke Holdings Limited Antimicrobial compositions
GB2550301B (en) * 2015-02-03 2019-12-11 Matoke Holdings Ltd Antimicrobial fibers and compositions
GB201716986D0 (en) 2017-10-16 2017-11-29 Matoke Holdings Ltd Antimicrobial compositions
WO2020158833A1 (ja) 2019-01-31 2020-08-06 セルメディシン株式会社 無機塩類タンパク複合医療機器

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JPH0622570B2 (ja) * 1989-01-31 1994-03-30 多木化学株式会社 生体材料
CH679207A5 (ja) 1989-07-28 1992-01-15 Debiopharm Sa
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CA2033046C (en) 1990-01-12 1999-08-03 Lowell Saferstein Process for preparing a neutralized oxidized cellulose product and its method of use
AU663328B2 (en) 1991-06-21 1995-10-05 Genetics Institute, Llc Pharmaceutical formulations of osteogenic proteins
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
GB9206509D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges containing active agents
US5730933A (en) * 1996-04-16 1998-03-24 Depuy Orthopaedics, Inc. Radiation sterilization of biologically active compounds
US5945128A (en) 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
GB2344519B (en) 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
DK2079767T3 (da) 2006-10-11 2014-10-27 Tolmar Therapeutics Inc Fremstilling af bionedbrydelige polyestere med lave burst-egenskaber ved ekstraktion med et superkritisk fluid
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
ATE530576T1 (de) * 2007-08-01 2011-11-15 Ethicon Inc Collagen-assoziierte peptide und ihre verwendung
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
JP5658175B2 (ja) * 2009-03-10 2015-01-21 メドプリン リジェネラティブ メディカル テクノロジーズ カンパニーリミテッド 人工硬膜及びその製造方法
JP5555928B2 (ja) 2009-08-28 2014-07-23 日本バイリーン株式会社 酵素含有ナノファイバーの製造方法、酵素含有ナノファイバー、この酵素含有ナノファイバーを含む不織布及びこの不織布を用いた反応装置
JP5479584B2 (ja) * 2010-05-07 2014-04-23 帝人株式会社 生体糊用補強材及びその製造方法
US8273369B2 (en) * 2010-05-17 2012-09-25 Ethicon, Inc. Reinforced absorbable synthetic matrix for hemostatic applications
EP2575775B1 (en) * 2010-06-01 2018-04-04 Baxter International Inc. Process for making dry and stable hemostatic compositions
JP5792442B2 (ja) * 2010-09-01 2015-10-14 帝人株式会社 細胞特異的ペプチドを含有する繊維構造体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
IN2014DN09621A (ja) 2015-07-31
US20150125511A1 (en) 2015-05-07
AU2013261308B2 (en) 2018-02-08
JP5746430B2 (ja) 2015-07-08
RU2695522C2 (ru) 2019-07-23
DK2851085T3 (da) 2019-09-09
CA2873602A1 (en) 2013-11-21
CN104284673B (zh) 2018-02-13
JPWO2013172468A1 (ja) 2016-01-12
PL2851085T3 (pl) 2019-12-31
BR112014028443A8 (pt) 2018-02-06
EP2851085A4 (en) 2015-04-15
MX2014013818A (es) 2015-05-11
HK1204947A1 (en) 2015-12-11
BR112014028443A2 (pt) 2017-06-27
TW201350147A (zh) 2013-12-16
TWI636799B (zh) 2018-10-01
KR20150023253A (ko) 2015-03-05
US10071061B2 (en) 2018-09-11
WO2013172468A1 (ja) 2013-11-21
KR102037555B1 (ko) 2019-10-28
EP2851085A1 (en) 2015-03-25
CN104284673A (zh) 2015-01-14
ES2746300T3 (es) 2020-03-05
CA2873602C (en) 2022-08-16
AU2013261308A1 (en) 2014-12-04
PT2851085T (pt) 2019-10-11
BR112014028443B1 (pt) 2021-01-19
RU2014150498A (ru) 2016-07-10
MX356545B (es) 2018-06-01

Similar Documents

Publication Publication Date Title
EP2851085B1 (en) Protein ccomposition sterilized by radiation
AU2012326211B2 (en) Stabilizers for hemostatic products
EP2851095B1 (en) Sheet molding and hemostatic material
EP2851083B1 (en) Radiation-sterilization-resistant protein composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/48 20060101AFI20150309BHEP

Ipc: A61K 38/00 20060101ALI20150309BHEP

Ipc: A61L 15/44 20060101ALI20150309BHEP

Ipc: A61K 9/70 20060101ALI20150309BHEP

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/48 20060101AFI20180814BHEP

Ipc: A61L 15/44 20060101ALI20180814BHEP

Ipc: A61K 38/00 20060101ALI20180814BHEP

Ipc: A61K 47/30 20060101ALI20180814BHEP

Ipc: A61K 9/70 20060101ALI20180814BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180920

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

Owner name: TEIJIN PHARMA LIMITED

Owner name: TEIJIN LIMITED

Owner name: KM BIOLOGICS CO., LTD.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1147532

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013057157

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190903

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2851085

Country of ref document: PT

Date of ref document: 20191011

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190926

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190926

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190402492

Country of ref document: GR

Effective date: 20191128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191026

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2746300

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013057157

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

26N No opposition filed

Effective date: 20200603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200513

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20211021 AND 20211027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190626

REG Reference to a national code

Ref country code: FI

Ref legal event code: PCE

Owner name: TEIJIN LIMITED

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20220822

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: KM BIOLOGICS CO., LTD.; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20220823

Ref country code: ES

Ref legal event code: PC2A

Owner name: KM BIOLOGICS CO., LTD.

Effective date: 20220927

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602013057157

Country of ref document: DE

Owner name: TEIJIN LIMITED, OSAKA-SHI, JP

Free format text: FORMER OWNERS: KM BIOLOGICS CO., LTD., KUMAMOTO-SHI, JP; TEIJIN LTD., OSAKA, JP; TEIJIN PHARMA LTD., TOKYO, JP

Ref country code: DE

Ref legal event code: R081

Ref document number: 602013057157

Country of ref document: DE

Owner name: KM BIOLOGICS CO., LTD., JP

Free format text: FORMER OWNERS: KM BIOLOGICS CO., LTD., KUMAMOTO-SHI, JP; TEIJIN LTD., OSAKA, JP; TEIJIN PHARMA LTD., TOKYO, JP

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 1147532

Country of ref document: AT

Kind code of ref document: T

Owner name: KM BIOLOGICS CO., LTD., JP

Effective date: 20221007

Ref country code: AT

Ref legal event code: PC

Ref document number: 1147532

Country of ref document: AT

Kind code of ref document: T

Owner name: TEIJIN LIMITED, JP

Effective date: 20221007

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1147532

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190626

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230414

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20230504

Year of fee payment: 11

Ref country code: PT

Payment date: 20230504

Year of fee payment: 11

Ref country code: NL

Payment date: 20230519

Year of fee payment: 11

Ref country code: IT

Payment date: 20230526

Year of fee payment: 11

Ref country code: IE

Payment date: 20230522

Year of fee payment: 11

Ref country code: FR

Payment date: 20230526

Year of fee payment: 11

Ref country code: DK

Payment date: 20230524

Year of fee payment: 11

Ref country code: DE

Payment date: 20230519

Year of fee payment: 11

Ref country code: CH

Payment date: 20230602

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230511

Year of fee payment: 11

Ref country code: SE

Payment date: 20230519

Year of fee payment: 11

Ref country code: PL

Payment date: 20230421

Year of fee payment: 11

Ref country code: GR

Payment date: 20230522

Year of fee payment: 11

Ref country code: FI

Payment date: 20230523

Year of fee payment: 11

Ref country code: AT

Payment date: 20230522

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230519

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230524

Year of fee payment: 11

Ref country code: ES

Payment date: 20230725

Year of fee payment: 11